Sucraid Single-Use Containers Approved for Congenital Sucrase-Isomaltase Deficienc
Sucraid is an oral enzyme replacement therapy of the genetically determined sucrase deficiency.
Diagnosis & Disease Information
Imfinzi Plus Chemotherapy Approved for Advanced Biliary Tract Cancer
The approval was based on data from the phase 3 TOPAZ-1 trial.
Immune-Modifying Nanoparticle Therapy Fast Tracked for Primary Biliary Cholangitis
The treatment is expected to reprogram the immune system to induce tolerance to PDC-E2.
Livmarli Approved for Cholestatic Pruritus in Alagille Syndrome
The approval was based on data from the phase 2b ICONIC study, along with 5 years of data from supportive studies.
Bylvay Approved for Progressive Familial Intrahepatic Cholestasis
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.
Devimistat Granted Orphan Drug Status for Biliary Cancer
Devimistat targets the mitochondrial tricarboxylic acid cycle selectively in cancer cells.
- Loading...
Loading...
Next post in News
Loading... 
Loading...